Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TC-510 · 1 trial · 17 indications
Phase 1 -The number and percent of patients in the DLT evaluable set who experienced DLTs from the first administration of study drug up to 28 days post study drug treatment will be summarized by dosing group
ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1
DCR defined as a composite of ORR and stable disease (SD) lasting at least 8 weeks.
| Arm | Type | Description |
|---|---|---|
| Lymphodepletion followed by TC-510 | EXPERIMENTAL | Lymphodepletion (fludarabine and cyclophosphamide) followed by TC-510 T cells |
| Name | Type | Description |
|---|---|---|
| TC-510 | BIOLOGICAL | TC-510 |
| Fludarabine | DRUG | Fludarabine |
| Cyclophosphamide | DRUG | Cyclophosphamide |
Inclusion Criteria: * Patient is \> 18 years of age at the time the Informed Consent is signed. * Patient has a pathologically confirmed diagnosis of either MPM, Serous Ovarian Adenocarcinoma, Pancreatic Adenocarcinoma, TNBC, and Colorectal Cancer * Patient's tumor has been reviewed with confirmed ...
Top 13 of 14 competitors
TC-510 is an investigational therapy being studied in patients with advanced mesothelin-expressing cancers, including mesothelioma. It is being developed for oncology indications and is currently in Phase 1 clinical development. It has not been approved for any use.
TC-510 targets mesothelin, a protein expressed on the surface of certain cancer cells. By binding to mesothelin, TC-510 is designed to act against tumors that express this protein. Mesothelin is a protein target, and the drug is a monoclonal antibody.
TC-510 is being developed by Adaptimmune Therapeutics PLC, which trades on the Nasdaq under the ticker ADAP. The company is the sponsor of the clinical program evaluating TC-510 in advanced mesothelin-expressing cancers.
TC-510 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The ongoing study is a Phase 1/2 trial, and the drug remains in early-stage testing for advanced mesothelin-expressing cancers.
TC-510 is being evaluated in one clinical trial, NCT05451849, titled A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer. The trial is active but not recruiting, has enrolled 6 patients, and is being conducted in the United States.